Purchase of Kirkstall and CLN - Correction

Summary by AI ^BETAClose X

Imaging Biometrics Limited (IBAI) has issued a correction to its previous announcement regarding the purchase of Kirkstall Limited and a convertible loan note (CLN) with Truetide plc. The correction pertains to the conversion price of the CLN, which is £0.0075 per Ordinary Share. The CLN bears interest at 6% per annum, accruing and adding to the loan balance. The loan is unsecured and subordinated and can be converted into IBAI Ordinary Shares at Truetide's discretion, either wholly or partially, at the lower of £0.0075 or the subscription price of any fundraising completed by IBAI before conversion. The final redemption date for the CLN is December 31, 2027. All other details from the original announcement remain unchanged.

Disclaimer*

Imaging Biometrics Limited

14 October 2025

Imaging Biometrics Limited
("IBAI" or the "Company")

Purchase of Kirkstall Limited and CLN with Truetide plc - Correction

The following amendment has been made to the Purchase of Kirkstall Limited and CLN with Trueside plc announcement released on 14.10.25 at 7am.

The conversion price of the convertible loan notes is £0.0075 per Ordinary Share. All other details remain unchanged.

The full amended text is shown below:

The CLN bears interest at 6% per annum, which will accrue and be added to the loan balance. It is unsecured and subordinated, and may be converted into Ordinary Shares of IBAI at the discretion of Truetide, in whole or in part, at the lower of £0.0075 (subject to a General Meeting to change the Company's par value) or the subscription price of any fundraising completed by IBAI prior to conversion. The final redemption date is 31 December 2027.

The Directors of the Company accept responsibility for the contents of this announcement.

- ENDS -

For further information:
Imaging Biometrics Limited
Tel: 01738 587555

Trevor Brown / Dr Al Musella / Brett Skelly / Michael Schmainda

Peterhouse Capital Limited
Tel: 020 7469 0936

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END